KidneyCcompanion - Medical Prescription Analysis Report

KidneyCompanion - Medical Prescription Analysis Report

Report Date: 2025-12-19 14:05

Patient Information:

Id: 69244ff257e2834a3d8f7994

Username: Aditya

Current Metrics: {'serum_creatinine': 2.1, 'egfr': 38.0, 'sodium': 137.0, 'potassium': 5.6, 'disease_prediction':

History: [{'date': '2025-11-24 18:00:42', 'metrics': {'serum_creatinine': 2.1, 'egfr': 38.0, 'sodium': 137.0, 'pota

Latest Lab Pdf: uploads/lab_reports/Aditya_kidney_stone_sample_lab_report_ckd.pdf

Egfr: 45

Potassium: 4.2

Sodium: 138

Serum Creatinine: 1.8

Blood Urea: 40

Has Diabetes: False

Has Hypertension: True

Stage: Stage 3b

Prescription Analysis:

Medications:

1. wdasd - 1-0-1 - 3days

Clinical Insights:

The prescribed medication 'wdasd' is not a recognized pharmaceutical name. Without knowing the specific drug, its class, mechanism of action, pharmacokinetics, and renal excretion profile, a detailed clinical analysis in the context of CKD Stage 3b (eGFR 45) is not possible. For patients with CKD Stage 3b, many medications require dose adjustments due to reduced renal

clearance, and some may be contraindicated. The patient's current eGFR of 45 indicates moderate reduction in kidney function. Other lab values (Potassium 4.2, Sodium 138, Serum Creatinine 1.8, Blood Urea 40) are within a range typically seen in CKD Stage 3b and do not immediately suggest acute issues, but these values must always be considered when introducing new medications. The absence of diabetes and hypertension simplifies some aspects, but the CKD itself remains a critical factor for medication management.

Recommendations:

It is critically important to identify the medication 'wdasd' immediately. Once identified, a thorough review of its pharmacokinetics, pharmacodynamics, and specific dosing guidelines for patients with CKD (eGFR 45) is essential. If the drug is renally cleared, a dose adjustment may be necessary, or the drug may need to be avoided. General recommendations for any new medication in CKD patients include close monitoring for signs of adverse effects, changes in kidney function (eGFR, serum creatinine), and electrolyte levels (especially potassium and sodium), depending on the known properties of the identified drug.

KidneyCompanion - Medical Prescription Analysis Report